Interim results from a phase 2 trial of tazbentetol for treatment of schizophrenia showed trends of improving positive and negative symptoms in patients via synaptic regeneration.1 The safety profile was overall favorable, and biomarker signals indicated improvements in cortical abnormalities associated with schizophrenia, according to interim analysis presented at the Schizophrenia International Research Society 2026 Annual Congress.
6 Likes
I bet they’ve skewed the data in their favor. All they want is money…
Interesting they named spg-302 that way. Hopefully it panns out and helps on symptoms across the board.
2 Likes
Nice find firemonkey
1 Like
Do you want to get better?
I do but there is distrust between myself and big pharma, when their greatest incentive is profit over people.
A healthy breakfast doesn’t stop being a healthy breakfast because it’s overpriced . What it does mean is that some struggle to afford that breakfast.
I am reminded of a poster, whose name I forget, who was justifiably highly regarded. Through no fault of his own he was unable to get his medication. He has never recovered from that.
Certainly the immoral profiteering of Big pharma is something that all decent people should condemn. That however is a separate issue re how well or not the medications work.
2 Likes
I think big pharma focuses too much on synthetic drugs.
And intermediates.
Psychedelics like psilocybin cubensis could be therapeutic but the research is blocked.
Plenty of natural substances and traditional medicines that work to alleviate mental health issues.
1 Like